Understand the source comparison
Does Pinealon Work for Pineal Peptide Research?: Comparison
Pinealon (Glu-Asp-Arg) Nuclear transcription factor upregulation (BDNF, NGF, GDNF) Moderate. Multiple rodent studies show neuroprotective effects, inconsistent replication Very Low. No peer-reviewed RCTs, one uncontrolled open-label trial 100–200 mcg/kg subcut
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Pinealon (Glu-Asp-Arg)
- Nuclear transcription factor upregulation (BDNF, NGF, GDNF)
- Moderate. Multiple rodent studies show neuroprotective effects, inconsistent replication
- Very Low. No peer-reviewed RCTs, one uncontrolled open-label trial
- 100–200 mcg/kg subcutaneous daily × 21–28 days
- Cellular activity is reproducible; translational evidence is absent
- Epithalon (Ala-Glu-Asp-Gly)
- Telomerase activation, circadian rhythm modulation
- Moderate. Rodent studies show extended lifespan and improved melatonin rhythms
- Very Low. No controlled human trials published
- 1 mg/kg subcutaneous every 48 hours × 10 doses
- Similar evidence gap as pinealon; more focus on epigenetic aging markers
- Cerebrolysin (porcine brain-derived peptides)
- Multimodal neurotrophic activity via multiple growth factor pathways
- High. Extensive preclinical validation in ischemic and traumatic brain injury models
- Moderate. Multiple RCTs in stroke and dementia, mixed outcomes
- Not applicable (approved pharmaceutical in Europe)
- FDA-unapproved in U.S. but has human clinical trial data
- Semax (Met-Glu-His-Phe-Pro-Gly-Pro)
- ACTH analog, modulates monoamine oxidase and BDNF expression
- High. Well-characterised molecular targets, replicated neuroprotective effects
- Low-Moderate. Small Russian RCTs, limited Western replication
- 300–600 mcg intranasal daily
- Better-characterised than pinealon but still lacks FDA recognition